Dynavax Technologies reported $37.92M in Gross Profit on Sales for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
TG Therapeutics TGTX:US 1.4M 743K
Adma Biologics ADMA:US $ -1M 0.72M
Agenus AGEN:US $ 10.06M 551K
Alexion Pharmaceuticals ALXN:US $ 1511.1M 71.5M
Amgen AMGN:US $ 4889M 478M
AstraZeneca AZN:LN 6.03B 627M
Astrazeneca AZN:US 6.03B 627M
Biogen BIIB:US $ 2315.3M 99.4M
Biomarin Pharmaceutical BMRN:US $ 374.63M 8.77M
Bristol Myers Squibb BMY:US $ 9252M 682M
Dynavax Technologies DVAX:US $ 37.92M 20.79M
Gilead Sciences GILD:US $ 4827M 235M
Glaxosmithkline GSK:US $ 5573M 566M
Gw Pharmaceuticals GWPH:US $ 140.66M 2.86M
Merk MRK:US $ 8718M 93M
Nektar Therapeutics NKTR:US $ 20.66M 2.77M
Neurocrine Biosciences NBIX:US $ 285.8M 52.1M
Novartis NOVN:VX 9.54B 679M
Pfizer PFE:US $ 11985M 1575M
Regeneron Pharmaceuticals REGN:US $ 4444.8M 2224.1M
Sarepta Therapeutics SRPT:US $ 144.57M 19.99M
Vertex Pharmaceuticals VRTX:US $ 1565.4M 33.42M